<?xml version="1.0" encoding="UTF-8"?>
<p>Resource allocation can be challenging, especially if a medical supply shortage occurs 
 <xref rid="onco13306-bib-0009" ref-type="ref">9</xref>. Medication shortage, mainly chemotherapy and narcotics, can cause significant negative impact in cancer care delivery. For cancers in which certain regimens are clinically preferred or no other therapeutic alternatives exist, drug shortages may be life‐threatening 
 <xref rid="onco13306-bib-0024" ref-type="ref">24</xref>. It is anticipated that the COVID‐19 pandemic will affect the medical product supply chains. On February 27, 2020, prior to the designation of pandemic, the U.S. Food and Drug Administration (FDA) issued a statement noting that one drug (drug was not named) is now in short supply because of COVID‐19 
 <xref rid="onco13306-bib-0025" ref-type="ref">25</xref>. As of March 21, 2020, the FDA Drug Shortages list contained 26 oncology medications 
 <xref rid="onco13306-bib-0026" ref-type="ref">26</xref>. While drug shortages might not manifest immediately, as many companies stockpile ingredients or supplies to protect against unexpected stoppages, identification and anticipation of such shortage can be particularly challenging during a pandemic 
 <xref rid="onco13306-bib-0027" ref-type="ref">27</xref>. Clear communication and transparency between stakeholders, suppliers, and health organizations is a must for successful implementation of strategies for managing drug shortages. The American Society of Health‐System Pharmacists suggested the following steps to overcome drug shortage: establishment of contact with other sites or health systems, as large health systems can often survive drug shortages by shifting drug inventory among sites; identification of alternative substitute therapies; and development of criteria for patient prioritization during drug shortages, with a multidisciplinary team involving pharmacy, medical, and nursing staff 
 <xref rid="onco13306-bib-0028" ref-type="ref">28</xref>.
</p>
